Rxsight, INC 8-K filings

RxSight, Inc. announced its second quarter 2026 financial results, reporting total revenue of $33.7 million, including $6.5 million from the Alcon collaboration, while product sales declined 19% year-over-year.

RxSight, Inc. announces a leadership transition with Aziz Mottiwala appointed as President and CEO, succeeding Dr. Ron Kurtz, who will move to Chief Medical Officer.

RxSight, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the re-election of three Class II directors and the ratification of its independent auditor.

RxSight, Inc. announced its first quarter 2026 financial results, reporting $30.9 million in sales and maintaining its full-year revenue and gross margin guidance.

RxSight, Inc. filed an amended 8-K to disclose the exact sign-on bonus amount and correct the stock option vesting schedule for its Chief Financial Officer, Mark Wilterding.

RxSight, Inc. announced its fourth quarter and full year 2025 financial results, showing strong Light Adjustable Lens growth but overall revenue decline and increased net losses, alongside a conservative 2026 guidance.

RxSight, Inc. announced preliminary unaudited Q4 and full-year 2025 financial results, surpassing its revenue guidance, and appointed Mark Wilterding as its new Chief Financial Officer.

RxSight, Inc. announced the finalization of transition and consulting agreements with outgoing CFO Shelley Thunen, affirming no impact on its full-year 2025 outlook.

RxSight, Inc. announced that Chief Financial Officer Shelley Thunen will transition from her role, effective by January 31, 2026, and will continue as a consultant.

RxSight, Inc. announced executive leadership changes, appointing Eric Weinberg as Chief Business Development Officer and Scott Gaines as Chief Customer Officer.

RxSight, Inc. announced a 14% decrease in third-quarter 2025 revenue to $30.3 million, despite a 6% increase in Light Adjustable Lens procedure volume, while narrowing full-year revenue guidance and raising gross margin expectations.

RxSight, Inc. announced the appointment of Raymond W. Cohen to its Compensation and Audit Committees, effective August 14, 2025.

RxSight, Inc. reported mixed second quarter 2025 financial results, with increased Light Adjustable Lens procedure volume offset by a decline in Light Delivery Device sales, leading to a 4% revenue decrease and expanded net loss, while reaffirming full-year guidance.

RxSight, Inc. announced the appointment of seasoned medical technology executive Raymond W. Cohen to its Board of Directors, expanding the board to ten members.

RxSight, Inc. announced preliminary second quarter 2025 financial results showing a revenue decrease and a significant downward revision of its full-year 2025 revenue guidance, driven by a sharp decline in Light Delivery Device sales.

RxSight, Inc. announced the successful re-election of its Class I directors, advisory approval of executive compensation, and ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

RxSight's first quarter 2025 revenue increased by 28% year-over-year to $37.9 million, fueled by strong sales of Light Adjustable Lenses and Light Delivery Devices.

RxSight reports preliminary Q1 2025 revenue of approximately $37.9 million and adjusts its full-year 2025 revenue guidance downward due to headwinds in the premium IOL market.

RxSight, Inc. announces a 41% increase in fourth-quarter revenue and a 57% increase in full-year revenue for 2024, driven by strong sales of Light Adjustable Lenses and Light Delivery Devices.

RxSight, Inc. reported preliminary unaudited fourth quarter and full-year 2024 financial results, exceeding initial revenue guidance and projecting continued growth for 2025.

RxSight, Inc. announced a 59% increase in revenue for the third quarter of 2024, driven by strong sales of its Light Adjustable Lenses and Light Delivery Devices, and raised its full-year revenue guidance.

RxSight, Inc. announced a 68% increase in revenue for the second quarter of 2024, driven by strong sales of its Light Adjustable Lens and Light Delivery Devices.

RxSight, Inc. successfully held its 2024 Annual Meeting, re-electing three Class III directors and approving executive compensation and the appointment of Ernst & Young LLP as its independent auditor.

RxSight, Inc. has announced the pricing of a public offering of 1,785,714 shares of its common stock at $56.00 per share, with an option for underwriters to purchase additional shares.

RxSight, Inc. announced a 69% increase in revenue for the first quarter of 2024, driven by strong sales of its Light Adjustable Lens technology.

RxSight, Inc. has entered into new leases and amendments for three of its four facilities in Aliso Viejo, California, extending their terms through January 31, 2031, and securing long-term operational space.

RxSight, Inc. announced a significant 82% increase in full-year 2023 revenue, driven by strong sales of its Light Adjustable Lens (LAL) and Light Delivery Devices (LDD).